Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
妇科肿瘤组 II 期临床试验中拉帕替尼和 EGFR 突变的潜在预后价值，用于治疗持续性或复发性子宫内膜癌
期刊:Gynecologic Oncology
影响因子:4.5
doi:10.1016/j.ygyno.2012.07.127
Kimberly K Leslie, Michael W Sill, Heather A Lankes, Edgar G Fischer, Andrew K Godwin, Heidi Gray, Russell J Schilder, Joan L Walker, Krishnansu Tewari, Parviz Hanjani, Ovadia Abulafia, Peter G Rose
